Celltrion Expands Brazil Portfolio with Autoimmune and Bone Therapies

Celltrion, a leading biopharmaceutical company, has announced the expansion of its portfolio in Brazil by introducing new treatments for autoimmune diseases and bone disorders. The company launched its autoimmune disease treatment, Koivolma, and bone disease treatments, Stovoclo and Osenbelt, in the Brazilian market on November 5, 2026.

Koivolma, a biosimilar to ustekinumab, is indicated for conditions such as plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is available in various formulations, including prefilled syringes and vials. The brand name was adapted to suit local linguistic preferences, differing from its name in other markets.

The new bone disease treatments, Stovoclo and Osenbelt, are also set to enhance Celltrion's offerings in Brazil. With this launch, the total number of products Celltrion sells in Brazil has increased to ten, including existing successful treatments like Remsima, Herzuma, and Truxima.

Celltrion aims to leverage its established sales network and relationships with healthcare providers to facilitate the rapid uptake of these new products. The company anticipates that the familiarity of hospitals and clinics with its existing products will aid in the adoption of Koivolma, Stovoclo, and Osenbelt.

Looking ahead, Celltrion plans to continue expanding its product lineup in Brazil, with additional therapies such as Eydenzelt and Abtozma expected to launch by the end of the year. A company representative stated, "We will push for early market establishment and broaden prescriptions for the new products based on the customer network and trust built with existing products."